Authors'reply

The Lancet

Volumn 381, Issue 9880, 2013, Pages 1812-1813

  Burmester, Gerd R ^a   Benda, Birgitta ^b   Gruben, David ^b   Bradley, John ^b   Mebus, Charles ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; PROTEIN ANTIBODY; RHEUMATOID FACTOR; TOFACITINIB; JANUS KINASE; METHOTREXATE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

BODY MASS; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; JANUS KINASES; MALE; METHOTREXATE; PYRIMIDINES; PYRROLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878104859     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/s0140-6736(13)61115-0     Document Type: Letter

References (2)

1. Burmester GR, Blanco R, Charles-Shoeman C, et al Tofacitinib (CP 690-550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60
2. Kremer J, Zerbini C, Lee E.B., et al Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analyses of efficacy endpoints by subgroups in a pooled phase 2 and 3 rheumatotid arthritis study population. Ann Rheum Dis 2012; 71: 203.